FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:62-63 January 5, 1995 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Socan and colleagues (Aug. 11 issue)¹ described an 18-year-old man with pneumonia and meningoencephalitis thought to be due to Chlamydia pneumoniae. Their diagnosis was based on serologic findings (high IgG and IgM antibody titers to C. pneumoniae by microimmunofluorescence assay at presentation, with declining titers thereafter), positive direct-immunofluorescence tests of the cerebrospinal fluid and throat washings, and the exclusion of many other likely agents.

Our experience is that the microimmunofluorescence test for C. pneumoniae antibody lacks both sensitivity and specificity for infection when it is compared with culture and the polymerase chain reaction.^2,3 This is especially true . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Temple, R., Ellenberg, S. S. (2000). Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues. ANN INTERN MED 133: 455-463 [Abstract] [Full Text]